Will Celldex Therapeutics, Inc. (CLDX) Short Squeeze Soon?

Faith Castro
June 7, 2017

The market capitalization of the company is at $366.25 Million. The Firm operates through three divisions: the Precision Bearing Components Group, the Precision Engineered Products Group and the Autocam Precision Components Group. It has a 16.82 P/E ratio. Within its Precision Bearing Components Group, it makes and supplies high precision bearing components, consisting of balls, cylindrical rollers, tapered rollers, spherical rollers and metal retainers, for bearing and constant velocity -joint. On average, equities analysts predict that Celldex Therapeutics will post ($1.11) earnings per share for the current year.

In terms of Buy, Sell or Hold recommendations, Celldex Therapeutics (NASDAQ:CLDX) has analysts' mean recommendation of 2.4. The company rocked its 52-Week High of $5.02 and touched its 52-Week Low of $2.72. The 1-year low was reported on Jun, 5 by Barchart.com. While the stock price moved along with the volume change, shares are touching $2.39.

The number of shares now held by investors is 125.11 Million.

Celldex Therapeutics (NASDAQ:CLDX)'s revenue estimates for the current quarter are $910 Million according to 7 number of analysts, for the current quarter the company has high revenue estimates of $1.87 Million in contradiction of low revenue estimates of $100 Million. It has underperformed by 37.32% the S&P500. A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range. The company was downgraded on Tuesday, March 8 by Jefferies. The median target of analyst views collected by Yahoo Finance was as much as $3.27 below CLDX's recent stock price. Oppenheimer maintained the stock with "Outperform" rating in Tuesday, August 11 report. Aegis reaffirmed a "buy" rating on shares of Celldex Therapeutics in a report on Tuesday, March 21st. (NASDAQ:CLDX) earned "Buy" rating by TH Capital on Tuesday, August 11. (NASDAQ:CLDX) were released by: Fool.com and their article: "Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc." published on May 21, 2017 as well as Fool.com's news article titled: "Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in ..." with publication date: May 09, 2017. The rating was downgraded by Guggenheim on Monday, March 7 to "Neutral".

More news: Trump pushes Gulf unity in call with Saudi king

Media stories about Celldex Therapeutics (NASDAQ:CLDX) have trended somewhat positive this week, according to AlphaOne Sentiment Analysis. The rating was downgraded by Wedbush to "Neutral" on Monday, March 7. The firm has "Outperform" rating given on Tuesday, March 8 by Cowen & Co. As per Tuesday, August 11, the company rating was maintained by Brean Capital. (NASDAQ:CLDX), a clinical-stage biotech developing targeted cancer therapies, took a few steps back last month.

More notable recent Celldex Therapeutics, Inc. Celldex Therapeutics Inc New now has $360.31 million valuation. A negative earnings surprise will usually result in a decline in share price.

Celldex Therapeutics, Inc.is a biopharmaceutical company. Of the analysts surveyed by Reuters that track WEC Energy Group, Inc. (NASDAQ:NNBR) to report earnings on August, 2. The stock now has Weekly Volatility of 4.45% and Monthly Volatility of 4.24%. The analysts estimated mean EPS at -0.28 while the high and low EPS estimate stand at -0.23 and -0.31 respectively. "VP & CFO CATLIN AVERY W on 2015-11-23 Sell 25000 shares of the company at a price of $18". NN, Inc. (NNBR) has risen 80.09% since June 5, 2016 and is uptrending.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by LeisureTravelAid

Discuss This Article